Jun 24

George Du Toit.

George Du Toit, M.B., B.Ch., Graham Roberts, D.M., Peter H. Sayre, M.D., Ph.D., Henry T. Bahnson, M.P.H., Suzana Radulovic, M.D., Alexandra F. Santos, M.D., Helen A. Brough, M.B., B.S., Deborah Phippard, Ph.D., Monica Basting, M.A., Mary Feeney, M.Sc., R.D., Victor Turcanu, M.D., Ph.D., Michelle L. Sever, M.S.P.H., Ph.D., Margarita Gomez Lorenzo, M.D., Marshall Plaut, M.D., and Gideon Lack, M.B., B.Ch. For the LEAP Study Team: Randomized Trial of Peanut Intake in Infants at Risk for Peanut Allergy.In addition to conference the prespecified primary efficacy endpoint of PANSS total score reduction, the analysis also met the prespecified essential secondary endpoint of improvement on the Clinical Global Impression – Improvement scale for each aripiprazole lauroxil group versus placebo at Week 12 . Both of the aripiprazole lauroxil dosing groupings demonstrated significant improvement at all post-baseline visits. Additionally, all other secondary endpoints were found to be statistically significant across both doses. Overall, 64 percent of sufferers who received aripiprazole lauroxil finished the study, in comparison to 46 percent of patients who received placebo.